-
1.
公开(公告)号:US20100227873A1
公开(公告)日:2010-09-09
申请号:US12770931
申请日:2010-04-30
申请人: Anandan Palani , Jing Su , Dong Xiao , Xianhai Huang , Ashwin U. Rao , Xiao Chen , Haiqun Tang , Jun Qin , Ying R. Huang , Robert G. Aslanian , Brian A. McKittrick , Syliva J. Degrado
发明人: Anandan Palani , Jing Su , Dong Xiao , Xianhai Huang , Ashwin U. Rao , Xiao Chen , Haiqun Tang , Jun Qin , Ying R. Huang , Robert G. Aslanian , Brian A. McKittrick , Syliva J. Degrado
IPC分类号: A61K31/519 , C07D491/052 , A61P9/00 , A61P25/00 , A61P35/00 , A61P29/00 , A61P11/00 , A61P1/00 , A61P3/10 , A61P7/00
CPC分类号: C07D491/04 , C07D471/04
摘要: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
摘要翻译: 本发明提供式(I)的化合物及其药学上可接受的盐,溶剂合物,酯和互变异构体,其中:Q选自:和L选自:药物组合物,其包含一种或多种 更多的式(I)化合物和使用式(I)化合物的方法。
-
公开(公告)号:US20130210805A1
公开(公告)日:2013-08-15
申请号:US13878654
申请日:2011-10-06
申请人: Robert G. Aslanian , Christopher W. Boyce , Robert D. Mazzola, JR. , Brian A. McKittrick , Kevin D. McCormick , Anandan Palani , Jun Qin , Haiqun Tang , Dong Xiao , Younong Yu , John P. Caldwell , Elizabeth Helen Kelley , Hongjun Zhang , Phieng Siliphaivanh , Rachel N. MacCoss , Joey L. Methot , Jolicia Polivina Gauuan , Qin Jiang , Andrew J. Leyhane , Johny Biju , Li Dong , Xian Huang , Ning Shao , Wei Zhou , Pawan K. Dhondi
发明人: Robert G. Aslanian , Christopher W. Boyce , Robert D. Mazzola, JR. , Brian A. McKittrick , Kevin D. McCormick , Anandan Palani , Jun Qin , Haiqun Tang , Dong Xiao , Younong Yu , John P. Caldwell , Elizabeth Helen Kelley , Hongjun Zhang , Phieng Siliphaivanh , Rachel N. MacCoss , Joey L. Methot , Jolicia Polivina Gauuan , Qin Jiang , Andrew J. Leyhane , Johny Biju , Li Dong , Xian Huang , Ning Shao , Wei Zhou , Pawan K. Dhondi
IPC分类号: C07D239/91 , A61K31/517 , A61K45/06 , C07D403/10 , C07D417/10 , C07D413/10 , C07D405/10 , C07D413/14 , C07D498/10 , C07D403/14 , A61K31/55 , C07D401/14 , A61K31/5395 , C07D471/04 , C07D401/10
CPC分类号: C07D239/91 , A61K31/517 , A61K31/5395 , A61K31/55 , A61K45/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/14 , C07D405/10 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/10 , C07D471/04 , C07D498/10
摘要: This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH2 receptor.
摘要翻译: 本申请提供式I化合物或其药学上可接受的盐,其中各个变量在本文中定义,以及制备这些化合物的方法,包含其的药物组合物及其用于治疗与CRTH2相关的疾病状态 受体。
-
公开(公告)号:US20110245209A1
公开(公告)日:2011-10-06
申请号:US13139912
申请日:2009-12-15
IPC分类号: A61K31/519 , C07D471/04 , A61K31/616 , A61P3/00 , A61P3/06 , A61P9/00 , A61P25/00 , A61P35/00 , A61P29/00 , A61P11/00 , A61P1/00 , A61P3/10 , A61P3/04 , A61P1/10 , A61P7/00
CPC分类号: C07D471/04
摘要: The present invention relates to Pyridopyrimidine Derivatives of formula (I), compositions comprising a Pyridopyrimidine Derivative and methods for using the Pyridopyrimidine Derivatives for treating or preventing a metabolic disorder, dyslipidemia, a cardiovascular disease, a neurological disorder, a hematological disease, cancer, inflammation, a respiratory disease, a gastroenterological disease, diabetes, a diabetic complication, obesity, an obesity-related disorder or non-alcoholic fatty liver disease.
摘要翻译: 本发明涉及式(I)的吡啶并嘧啶衍生物,包含吡啶并嘧啶衍生物的组合物和用于治疗或预防代谢紊乱,血脂异常,心血管疾病,神经障碍,血液病,癌症,炎症的吡啶并嘧啶衍生物的方法 呼吸系统疾病,胃肠疾病,糖尿病,糖尿病并发症,肥胖症,肥胖相关病症或非酒精性脂肪性肝病。
-
4.
公开(公告)号:US08598158B2
公开(公告)日:2013-12-03
申请号:US13515638
申请日:2010-12-09
申请人: Dong Xiao , Anandan Palani , Robert G. Aslanian , Sylvia Degrado , Xianhai Huang , Wei Zhou , Michael Sofolarides , Xiao Chen
发明人: Dong Xiao , Anandan Palani , Robert G. Aslanian , Sylvia Degrado , Xianhai Huang , Wei Zhou , Michael Sofolarides , Xiao Chen
IPC分类号: C07D417/02 , C07D417/14 , A61K31/55 , A61P29/00
CPC分类号: A61K31/55 , C07D491/048 , C07D495/04
摘要: The present invention relates to certain lactam ring-containing compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein D, E, X1, R1, R2, R3, R4, R9, and R10 are as herein described. In addition, the invention relates to pharmaceutically acceptable compositions comprising at least one such compound, and methods of using the compounds for treating or preventing various inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, and chronic obstructive pulmonary disorder.
摘要翻译: 本发明涉及式(I)的某些含内酰胺环的化合物及其药学上可接受的盐,其中D,E,X 1,R 1,R 2,R 3,R 4,R 9和R 10如本文所述。 此外,本发明涉及包含至少一种此类化合物的药学上可接受的组合物,以及使用该化合物治疗或预防各种炎性疾病如类风湿性关节炎,炎性肠病,牛皮癣,哮喘和慢性阻塞性肺病的方法。
-
公开(公告)号:US20110207734A1
公开(公告)日:2011-08-25
申请号:US13086660
申请日:2011-04-14
申请人: Anandan Palani , Dong Xiao , Robert G. Aslanian , Michael Y. Berlin , Ashwin U. Rao , Xiao Chen , Yoon Joo Lee , Sylvia Degrado , Ning Shao , Ying R. Huang , Zhidan Liu
发明人: Anandan Palani , Dong Xiao , Robert G. Aslanian , Michael Y. Berlin , Ashwin U. Rao , Xiao Chen , Yoon Joo Lee , Sylvia Degrado , Ning Shao , Ying R. Huang , Zhidan Liu
IPC分类号: A61K31/5377 , C07D401/12 , A61K31/4545 , C07D401/14 , C07D401/06 , A61K31/496 , C07D413/14 , A61K31/4725 , C07D417/14 , A61K31/506 , A61P11/00 , A61P37/08 , A61P11/02 , A61P29/00 , A61P9/00 , A61P1/00 , A61P25/00 , A61P3/00 , A61P3/04 , A61P3/10 , A61P3/08
CPC分类号: C07D401/06 , C07D213/643 , C07D213/81 , C07D401/12 , C07D417/04
摘要: The present invention relates to Azine Derivatives, pharmaceutical compositions comprising the Azine Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.
摘要翻译: 本发明涉及Azine衍生物,包含Azine衍生物的药物组合物和这些化合物用于治疗或预防过敏,使用过敏引起的气道反应,充血,心血管疾病,炎性疾病,胃肠道疾病,神经障碍 ,代谢紊乱,肥胖或肥胖相关疾病,糖尿病,糖尿病并发症,葡萄糖耐量降低或空腹血糖受损。
-
公开(公告)号:US07884080B2
公开(公告)日:2011-02-08
申请号:US11854754
申请日:2007-09-13
申请人: Robert G. Aslanian , Chad E. Bennett , Duane A. Burnett , Tin-Yau Chan , Eugenia Y. Kiselgof , Chad E. Knutson , Joel M. Harris , Brian A. McKittrick , Anandan Palani , Elizabeth M. Smith , Henry M. Vaccaro , Dong Xiao , Hyunjin M. Kim
发明人: Robert G. Aslanian , Chad E. Bennett , Duane A. Burnett , Tin-Yau Chan , Eugenia Y. Kiselgof , Chad E. Knutson , Joel M. Harris , Brian A. McKittrick , Anandan Palani , Elizabeth M. Smith , Henry M. Vaccaro , Dong Xiao , Hyunjin M. Kim
IPC分类号: C07D471/10 , A61K31/397 , A61P3/06 , A61P3/10
CPC分类号: C07D471/10
摘要: The present invention relates to Azetidinone Derivatives of structural formula 1: and compositions comprising an Azetidinone Derivative and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of an Azetidinone Derivative.
摘要翻译: 本发明涉及结构式1的氮杂环丁酮衍生物和包含氮杂环丁酮衍生物的组合物和用于治疗或预防脂质代谢紊乱,疼痛,糖尿病,血管病症,脱髓鞘或非酒精性脂肪性肝病的方法,包括给予患者 有效量的氮杂环丁酮衍生物。
-
7.
公开(公告)号:US07750015B2
公开(公告)日:2010-07-06
申请号:US11600216
申请日:2006-11-15
申请人: Anandan Palani , Dong Xiao , Xianhai Huang , Ashwin U. Rao , Xiao Chen , Jun Qin , Ying R. Huang , Robert G. Aslanian , Sylvia J. Degrado
发明人: Anandan Palani , Dong Xiao , Xianhai Huang , Ashwin U. Rao , Xiao Chen , Jun Qin , Ying R. Huang , Robert G. Aslanian , Sylvia J. Degrado
IPC分类号: C07D491/052 , A61K31/519 , A61P9/00 , A61P25/00 , A61P35/00 , A61P29/00 , A61P11/00 , A61P1/00 , A61P3/10
CPC分类号: C07D491/052
摘要: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
摘要翻译: 本发明提供式(I)化合物及其药学上可接受的盐,溶剂合物,酯和互变异构体,其中:Q选自:L选自:包含一种或多种 式(I)化合物和使用式(I)化合物的方法。
-
公开(公告)号:US20110243940A1
公开(公告)日:2011-10-06
申请号:US13139890
申请日:2009-12-15
申请人: Dong Xiao , Anandan Palani , Xianhai Huang , Xiaohong Zhu , Robert G. Aslanian
发明人: Dong Xiao , Anandan Palani , Xianhai Huang , Xiaohong Zhu , Robert G. Aslanian
IPC分类号: A61K39/395 , C07D491/052 , A61K31/435 , A61K31/505 , A61K31/47 , A61K31/397 , A61K31/60 , A61K31/4162 , A61P3/10 , A61P35/00 , A61P11/00 , A61P1/00 , A61P25/00 , A61P3/04
CPC分类号: C07D491/052
摘要: The present invention relates to Bicyclic Pyranone Derivatives, their compositions and uses for treating or preventing a metabolic disorder, dyslipidemia, a cardiovascular disease, a neurological disorder, a hematological disease, cancer, inflammation, a respiratory disease, a gastroenterological disease, diabetes, a diabetic complication, obesity, an obesity-related disorder or non-alcoholic fatty liver disease. Formula (I). Y is —C— when an optional and additional bond is present and Y is —CH— when an optional and additional bond is not present; Z is —O—, —NH— or —N(alkyl)- when the optional and additional bond between Y and Z Is absent, and Z Is —N— when the optional and additional bond between Y and Z is present; R1 is H1 halo or —CN; R2 is alkyl, alkenyl or -(alkyleneVcydoalkyl; t is 0 or 1; R3 is O when the optional and additional bond between Y and R3 is present, and R3 is alkyl.haloalkyl.—C(0)0R5.-alkylene-O-alkyt or —O-alkyl when the optional and additional bond between Y and R3 is absent: R4 is H, alkyl or aryl, wherein an aryl group can be unsubstituted or optionally substituted.
摘要翻译: 本发明涉及双环吡喃酮衍生物,其组合物和用于治疗或预防代谢紊乱,血脂异常,心血管疾病,神经障碍,血液病,癌症,炎症,呼吸系统疾病,胃肠病,糖尿病, 糖尿病并发症,肥胖症,肥胖相关障碍或非酒精性脂肪性肝病。 式(I)。 当不存在任选和另外的键时,当存在任选的附加键且Y是-CH-时,Y是-C-; 当Y和Z之间的任选和另外的键不存在时,Z是-O - , - NH-或-N(烷基),当存在Y和Z之间的任选的和另外的键时,Z是 - R1为H1卤素或-CN; R 2是烷基,烯基或 - (亚烷基二烷基; t是0或1;当存在Y和R 3之间的任选和另外的键时,R 3是O,R 3是烷基卤代烷基-C(O) - 烷基或-O-烷基,当Y和R3之间的任选和另外的键不存在时:R4是H,烷基或芳基,其中芳基可以是未取代的或任选被取代的。
-
9.
公开(公告)号:US20110152259A1
公开(公告)日:2011-06-23
申请号:US13033895
申请日:2011-02-24
申请人: Anandan Palani , Jing Su , Dong Xiao , Xianhai Huang , Ashwin U. Rao , Xiao Chen , Haiqun Tang , Jun Qin , Ying R. Huang , Robert G. Aslanian , Brain A. McKittrick , Syliva J. Degrado
发明人: Anandan Palani , Jing Su , Dong Xiao , Xianhai Huang , Ashwin U. Rao , Xiao Chen , Haiqun Tang , Jun Qin , Ying R. Huang , Robert G. Aslanian , Brain A. McKittrick , Syliva J. Degrado
IPC分类号: A61K31/5377 , C07D491/052 , A61K31/519 , C07D413/14 , A61P3/00 , A61P7/00 , A61P35/00 , A61P11/00
CPC分类号: C07D491/04 , C07D471/04
摘要: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
摘要翻译: 本发明提供式(I)的化合物及其药学上可接受的盐,溶剂合物,酯和互变异构体,其中:Q选自:和L选自:药物组合物,其包含一种或多种 更多的式(I)化合物和使用式(I)化合物的方法。
-
10.
公开(公告)号:US07737155B2
公开(公告)日:2010-06-15
申请号:US11771538
申请日:2007-06-29
申请人: Anandan Palani , Dong Xiao , Xianhai Huang , Ashwin U. Rao , Xiao Chen , Jun Qin , Ying R. Huang , Robert G. Aslanian
发明人: Anandan Palani , Dong Xiao , Xianhai Huang , Ashwin U. Rao , Xiao Chen , Jun Qin , Ying R. Huang , Robert G. Aslanian
IPC分类号: C07D491/052 , A61K31/519 , A61P9/00 , A61P25/00 , A61P33/00 , A61P29/00 , A61P1/00 , A61P3/10
CPC分类号: C07D491/04 , C07D471/04
摘要: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
摘要翻译: 本发明提供式(I)的化合物及其药学上可接受的盐,溶剂合物,酯和互变异构体,其中:Q选自:和L选自:药物组合物,其包含一种或多种 更多的式(I)化合物和使用式(I)化合物的方法。
-
-
-
-
-
-
-
-
-